Use Of A Hydroximic Acid Halide Derivative In The Treatment Of Neurodegenerative Diseases

Abstract

The invention relates to the use of a chemical substance selected from the group consisting of N-′2-hydroxy-3-(1-piperidinyl)-propoxyl !-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixtures of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compounds in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.

1 . Use of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, an optically active enantiomer or mixture of enantiomers thereof and a pharmaceutically acceptable salt of the racemic or optically active compound in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases. 
   
   
       2 . An use as claimed in  claim 1  wherein the chemical substance is (+)-R—N-[2-hydroxy-3-(1-piperidinyl)propoxy]-pyridine-1-oxide-3-carboximidoyl chloride. 
   
   
       3 . An use as claimed in  claim 2  wherein the chemical substance is a salt of (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride. 
   
   
       4 . An use as claimed in  claim 3  wherein the chemical substance is (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate. 
   
   
       5 . An use as claimed in any of  claims 1  to  4  wherein the neurodegenerative disease is amyotrophic lateral sclerosis. 
   
   
       6 . Method of treatment or prevention of a neurodegenerative disease wherein a therapeutically effective amount of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, an optically active enantiomer or mixture of enantiomers thereof and a pharmaceutically acceptable salt of the racemic or optically active compound is administered to a patient. 
   
   
       7 . A method as claimed in  claim 6  wherein the chemical substance is (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride. 
   
   
       8 . A method as claimed in  claim 7  wherein the chemical substance is a salt of (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carbox-imidoyl chloride. 
   
   
       9 . A method as claimed in  claim 8  wherein the chemical substance is (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate. 
   
   
       10 . A method as claimed in any of  claims 6  to  9  wherein the neurodegenerative disease is amyotrophic lateral sclerosis.